Navigation Links
PETA files complaint with European ombudsman over animal testing for REACH
Date:7/27/2012

London The People for the Ethical Treatment of Animals (PETA) Foundation UK has submitted a complaint to the European ombudsman today alleging that the European Chemicals Agency (ECHA) is failing to fulfil its mandated responsibilities by not properly investigating cases in which animal testing could be avoided under the rules of REACH. The European ombudsman investigates complaints about maladministration in EU institutions and agencies, and PETA maintains that evidence derived from public documents and correspondence with the agency demonstrates that ECHA is not taking the necessary steps to ensure that REACH's legal requirement that animal testing be conducted only as a "last resort" are fulfilled.

The REACH Regulation (1907/2006/EU) makes clear in recitals, articles and annexes that animal tests must be avoided wherever possible, but in 2011 the agency's report "The Use of Alternatives to Testing on Animals for the REACH Regulation" showed that tens of thousands of animals were used in tests that could have been avoided under REACH's own rules. These tests included 135 skin-irritation studies conducted after a non-animal replacement had been validated and approved for use under REACH and 107 studies conducted without prior submission and approval of a testing proposal.

In response to the report, PETA UK contacted ECHA and the European Commission to seek assurances that all such possible violations of the requirements were being investigated by the agency and/or notified to relevant national authorities. These enquiries have revealed the following:

  1. ECHA is not taking action to investigate all the 107 tests conducted without test proposals and will not routinely investigate similar cases in the future.
  2. ECHA does not directly inform member state authorities of all possible violations of last-resort requirements identified by its own internal processes.
  3. During compliance checks, ECHA evaluates only whether or not adaptations to animal test requirements comply with the REACH Regulation, not whether animal tests themselves could have been avoided.

PETA UK has therefore submitted a complaint to the ombudsman, which notes that in failing to take appropriate action to evaluate compliance of animal tests with REACH's requirements, the agency is guilty of maladministration.

"REACH has multiple mechanisms to mitigate its massive impact on animals, but the European institution responsible for ensuring REACH compliance is simply not ensuring that all of those mechanisms are being implemented," says PETA UK policy adviser Alistair Currie. "We have pursued this issue with ECHA itself and with the European Commission but without resolution. With millions of animals' lives at stake, we trust that the ombudsman will take our view that the agency is failing to fulfil its obligations."


'/>"/>

Contact: Jessica Sandler
JessicaS@PETA.org
757-622-7382 x8001
People for the Ethical Treatment of Animals
Source:Eurekalert

Related biology news :

1. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
2. An invasive Asian fly is taking over European fruit
3. Building the European Unions Natura 2000 -- the largest ever network of protected areas
4. European grasslands challenge rainforests as the most species-rich spaces on Earth
5. European mountain plant population shows delayed response to climate change
6. European Society of Human Reproduction and Embryology 28th Annual Meeting -- Istanbul
7. Citizen science helps unlock European genetic heritage
8. Parkinsons disease stopped in animal model
9. Study suggests why some animals live longer
10. Are we really a nation of animal lovers?
11. NOAA discovers way to detect low-level exposure to seafood toxin in marine animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology: